Novel 5-membered ring heterocycles, their preparation, their use and pharmaceutical preparations comprising them
CA 2247735 A1 · Owner: Sanofi-Aventis Deutschland Gmbh · Inventors: Seiffge, Dirk; Wehner, Volkmar; Schmidt, Wolfgang
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to compounds of the formula I in which B, E, W, Y, Z, R, R2, R2a, R2b R3, g and h have the meanings, indicated in the claims. The compounds of the formula I are valuable pharmaceutical active compounds, which are suitable for example, for the, therapy and prophylaxis of inflammatory disorders for example of, rheumatoid arthritis, or of allergic disorders. The compounds of the formula I are inhibitors of the adhesion and migration of leucocytes and/or antagonists of the adhesion receptor VLA-4 belonging to the integrins group. They are generally suitable for the therapy or prophylaxis of illnesses which are caused by an undesired extent of leucocyte adhesion …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 21, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 21, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 21, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.